GlassScriptPhysician profile
Michelle Duplantis
NPI 1457742199
$8,265.37
in general payments reported to CMS, 2019-2025
47 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,491 · 2022: $1,875 · 2023: $1,937 · 2024: $1,251 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,867 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,866.80 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,522.16 | 2021-2025 | |
| Glaxosmithkline, LLC. | $658.90 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $615.49 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $609.11 | 2022-2025 | Repatha, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $563.21 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| Novo Nordisk INC | $494.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $480.95 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $444.77 | 2021-2025 | Trintellix |
| Abbott Laboratories | $367.00 | 2022-2025 | Freestyle Libre 3, Freestyle Libre |
| Janssen Pharmaceuticals, INC | $276.35 | 2021-2025 | Spravato |
| Merck Sharp & Dohme LLC | $193.43 | 2021-2025 | Belsomra, Steglatro, Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.91 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $142.46 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $131.55 | 2022-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $127.76 | 2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Duplantis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.